BioCentury | Aug 3, 2015
Company News

Chiome, ADC Therapeutics deal

...Chiome’s LivTech Inc. subsidiary granted ADC an option for exclusive, worldwide rights to develop LIV-1205 as an...
...worldwide rights to develop LIV-1205 as an antibody-drug conjugate (ADC) to treat cancer. Upon exercise, LivTech...
...LIV-1205 is a humanized mAb against cell surface antigen delta-like 1 (DLL1) in preclinical development. LivTech...
BioCentury | Apr 6, 2015
Finance

Up, up and acquired

...while Chiome fell after announcing it would acquire the remaining minority stake of antibody company LivTech Inc....
...Mich. Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Intercept Pharmaceuticals Inc. (NASDAQ:ICTP), New York, N.Y. LivTech Inc....
BioCentury | Nov 14, 2011
Company News

LivTech, Yakult deal

...Yakult received an option to license exclusive, worldwide rights to develop and commercialize LivTech's preclinical LIV-2008...
...preclinical and chemistry, manufacturing and controls (CMC) studies funded by Yakult during the option period. LivTech...
...and is eligible for milestones until the option is exercised. If Yakult exercises its option, LivTech...
Items per page:
1 - 3 of 3
BioCentury | Aug 3, 2015
Company News

Chiome, ADC Therapeutics deal

...Chiome’s LivTech Inc. subsidiary granted ADC an option for exclusive, worldwide rights to develop LIV-1205 as an...
...worldwide rights to develop LIV-1205 as an antibody-drug conjugate (ADC) to treat cancer. Upon exercise, LivTech...
...LIV-1205 is a humanized mAb against cell surface antigen delta-like 1 (DLL1) in preclinical development. LivTech...
BioCentury | Apr 6, 2015
Finance

Up, up and acquired

...while Chiome fell after announcing it would acquire the remaining minority stake of antibody company LivTech Inc....
...Mich. Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Intercept Pharmaceuticals Inc. (NASDAQ:ICTP), New York, N.Y. LivTech Inc....
BioCentury | Nov 14, 2011
Company News

LivTech, Yakult deal

...Yakult received an option to license exclusive, worldwide rights to develop and commercialize LivTech's preclinical LIV-2008...
...preclinical and chemistry, manufacturing and controls (CMC) studies funded by Yakult during the option period. LivTech...
...and is eligible for milestones until the option is exercised. If Yakult exercises its option, LivTech...
Items per page:
1 - 3 of 3